Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said it has inked an agreement with an unnamed Nasdaq-listed biopharmaceutical entity aimed at developing an optimised drug for a metabolic condition - one that harnesses the company's oral delivery system.
Under the terms of this agreement, Poolbeg will receive funding to work alongside its new partner in creating a prototype drug.
Poolbeg hopes the strategic partnership will eventually evolve into a full licensing agreement.
"Our partner recognises the benefits of Poolbeg's licensed oral delivery technology and we look forward to optimising the development of this innovative drug for patients in an area where there is a clear unmet need," said CEO Jeremy Skillington.
Here's the interview with Poolbeg.
